GE Healthcare Patent-Cliff Exposure & CMS Drug Spending Portfolio
GE Healthcare (US): 9 reconciled FDA prescription therapies, $119.5M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 9 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2028-01-01 |
| 2024 CMS Total Public Spend | $119.5M |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $119.5M |
| California HCAI SB 17 Filings | 3 WAC filings (max 27.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for GE HealthCare across sibling Meru public-data platforms.